Corporate presentation
Logotype for Cosciens Biopharma Inc

Cosciens Biopharma (CSCI) Corporate presentation summary

Event summary combining transcript, slides, and related documents.

Logotype for Cosciens Biopharma Inc

Corporate presentation summary

13 Nov, 2026

Strategic reset and acquisition

  • 2025 actions included board reconstitution, Ceapro and corporate cost reductions, and a leadership transition focused on streamlining operations and sustainable growth.

  • Ceasing funding German subsidiaries in March 2026 initiated insolvency proceedings, eliminated ongoing operating-loss exposure and resulted in $10.9M of discontinued-operations income and a 4X gain in shareholders’ equity.

  • Shareholders approved a 1-for-150 consolidation followed by a 50-for-1 split, reducing shares by approximately two-thirds; the July 2026 Form 15 filing was intended to save ~$1.9M in annual U.S. reporting costs.

  • The portfolio now combines Ceapro’s oat-derived natural ingredients with Nualtis’ oral-film drug delivery, development and manufacturing capabilities.

Ceapro platform

  • Edmonton-based operations develop and manufacture oat-derived plant actives at a 30,000 sq. ft. GMP facility with R&D, pilot and commercial-scale capabilities.

  • Core ingredients include oat beta glucan, avenanthramides, superfine oat flour, oat oil and oat peptides for skin care, hair care, sensitive skin, and animal and pet applications.

  • Proprietary extraction, ethanol fractionation and chromatography support a documented, non-GMO portfolio; process work targets improved recovery and production efficiency across several oat ingredients.

  • Distribution partners provide formulation support, local regulatory expertise and access to brand owners across Europe, North America, Latin America and Asia.

  • 9M 2026 revenue was $7.5M, up 43% YoY; gross margin was 52%, versus 33% in 2025, and annualized EBITDA run rate was ~$2.5M.

Nualtis platform and pipeline

  • Montreal-based Nualtis offers VersaFilm for human health and VetaFilm for veterinary use, backed by 20+ years of GMP experience and 30+ U.S. patents and patent applications.

  • Oral thin films address a stated $3.8B global market in 2024, forecast to reach $8.4B by 2033 at 9.3% CAGR.

  • Pipeline spans human and animal health, including migraine, chronic pain, opioid use disorder, erectile dysfunction, CNS disorders and OTC products; revenue streams include R&D services, manufacturing and supply, milestones and royalties.

  • Multiple pipeline assets are in approval-stage development or progressing toward commercialization; partners include Gensco Pharma, Xiromed, OrthoNu, Kesin Pharma and Covenant Animal Health.

  • Nualtis and its partners face ongoing patent litigation concerning a proposed buprenorphine product; an adverse outcome could materially delay a commercial launch.

Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.
All investor relations material. One API.
Learn more

Latest events from Cosciens Biopharma